. Author manuscript; available in PMC: 2018 Jul 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2017 May 18;80(1):29–36. doi: 10.1007/s00280-017-3315-8

Table 1. Summary of patient demographics and disease characteristics by hepatic impairment status.

Parameter	Normal^* n = 9	Mild^* n = 8	Moderate^* n = 8	Severe^* n = 6
Median age, years (range)	67 (37–79)	64.5 (36–82)	68 (47–77)	65 (51–75)
Male, n (%)	8 (88.9)	5 (62.5)	6 (75)	5 (83.3)
ECOG 0/1/2, n (%)	3 (33.3)/6 (66.7)/0	2 (25)/4 (50)/2 (25)	0/8 (100)/0	0/5 (83.3)/1 (16.7)
Cancer diagnosis
Basal cell carcinoma, n (%)	1 (11.1)	0	0	0
Colorectal cancer, n (%)	2 (22.2)	0	0	1 (16.7)
Hepatocellular carcinoma, n (%)	5 (55.6)	5 (62.5)	6 (75)	5 (83.3)
Other cancer, n (%)	1 (11.1) (oropharyngeal)	3 (37.5) (renal cell carcinoma, ovarian and breast, and ocular melanoma)	2 (25) (appendiceal and cholangiocarcinoma)	0

ECOG Eastern Cooperative Oncology Group performance status.

Normal (bilirubin [bili] < upper limit of normal [ULN]) ], mild (ULN < bili ≤ 1.5 × ULN), moderate (1.5 × ULN < bili ≤ 3 × ULN), and severe (3 × ULN < bili < 10 × ULN) liver dysfunction.